<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Mutations in PIK3CA [the gene encoding the p110α catalytic subunit of phosphatidylinositide-3-kinase (PI3K)] play an important role in colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Experimental evidence suggests that PIK3CA exon 9 and exon 20 mutations trigger different biologic effects, and that concomitant mutations in both exons 9 and 20 synergistically enhance tumorigenic effects </plain></SENT>
<SENT sid="2" pm="."><plain>Thus, we hypothesized that PIK3CA exon 9 and exon 20 mutations might have differential effects on clinical outcome in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and that concomitant PIK3CA exon 9 and 20 mutations might confer aggressive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> behavior </plain></SENT>
<SENT sid="3" pm="."><plain>EXPERIMENTAL DESIGN: We sequenced PIK3CA by pyrosequencing in 1,170 rectal and <z:hpo ids='HP_0003003'>colon cancers</z:hpo> in two prospective cohort studies, and found 189 (16%) PIK3CA mutated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Mortality HR according to PIK3CA status was computed using Cox proportional hazards model, adjusting for clinical and molecular features, including microsatellite instability, CpG island methylator phenotype, LINE-1 methylation, and BRAF and KRAS mutations </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Compared with PIK3CA <z:mp ids='MP_0002169'>wild-type</z:mp> cases, patients with concomitant PIK3CA mutations in exons 9 and 20 experienced significantly worse <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival [log-rank P = 0.031; multivariate HR = 3.51; 95% confidence interval (CI): 1.28-9.62] and overall survival (log-rank P = 0.0008; multivariate HR = 2.68; 95% CI: 1.24-5.77) </plain></SENT>
<SENT sid="6" pm="."><plain>PIK3CA mutation in either exon 9 or 20 alone was not significantly associated with patient survival </plain></SENT>
<SENT sid="7" pm="."><plain>No significant interaction of PIK3CA mutation with BRAF or KRAS mutation was observed in survival analysis </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Coexistence of PIK3CA (the PI3K p110α subunit) exon 9 and 20 mutations, but not PIK3CA mutation in either exon 9 or 20 alone, is associated with poor prognosis of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
</text></document>